Sware Raises $6M to Accelerate Life Sciences Innovation by Automating FDA-Mandated Software Validation
Sware Adds AI Assistance to Res_Q Platform, Receives SOC 2 Type II Certification
Sware’s AI-supported tools and new certification affirm company’s commitment to deliver leading-edge technology for life sciences companies supported by industry best practices
September 3, 2024 10:00 AM EST | Boston | Business Wire
Sware, provider of the most complete software validation solution for innovative life sciences, software, and technology companies today announced that it has added AI Assistance to its Res_Q™ platform, a GxP validation platform that helps life sciences and biotechnology companies automate, unify, and accelerate validation processes. It comes as part of a larger, major update (24.2) that offers users multiple functional and quality-of-life changes for reporting, document review, quality assurance, and more. Additionally, the company received a System and Organizational Controls 2 Type II (SOC 2 Type II) certification following a successful external audit by Sensiba LLP, demonstrating strict systems controls in multiple domains including security, availability, and confidentiality.
Res_Q’s new AI Assistance feature helps users accelerate content creation and ensure consistency across document sets within the platform, making documentation and file management easier, faster, and more efficient. For example, a new AI-powered feature can now ingest and summarize large volumes of release notes, streamlining a core step in the validation process. The addition of AI Assistance to Res_Q is the first of several planned steps in Sware’s broader AI integration roadmap, which will focus on building Quality directly into AI-supported validation and supporting responsible use at all points in the GxP validation process.
Sware’s recently awarded SOC 2 Type II certification reflects the company’s ongoing commitment to upholding the highest quality standards possible in development, deployment, and operation. Notably, Sware’s SOC 2 Type II report did not have any noted exceptions and was therefore issued with a “clean” audit opinion from Sensiba. This indicates that Sware demonstrated an exceptionally high degree of rigor throughout the audit process.
“Sware has always strived to implement high-value features rooted in unparalleled domain knowledge and proven best practices,” said Ellen Reilly, CEO of Sware. “The addition of AI Assistance to Res_Q, in tandem with our SOC 2 Type II certification, demonstrates our capability to deliver customers leading-edge solutions backed by exceptional rigor, knowledge, and service. We look forward to announcing new functionalities, including additional AI-based capabilities, as we continue to enhance the Res_Q platform.”
About Res_Q
Res_Q is a cloud-based platform built with an open API architecture that allows life sciences organizations to control all validation processes – for IT, manufacturing, lab systems, and more – in a single, highly scalable system. With intelligent risk assessments to initiate workflows and assign workloads based on risk profile, Res_Q puts quality at the forefront without sacrificing speed.
About SOC 2 Type II
Developed by the American Institute of Certified Public Accountants (AICPA), the SOC 2 information security audit provides a report on the examination of controls relevant to the trust services criteria categories covering security, availability and confidentiality. A SOC 2 Type II report describes a service organization's systems, whether the design of specified controls meets the relevant trust services categories, and – as a follow-up to Type I – assesses the effectiveness of those controls over a specified period.
About Sware
Sware’s mission is to rescue life sciences companies from the grip of validation debt; the unpaid cost of release, testing, GxP, and business requirements. The Res_Q™ software platform offers the most complete validation solution available today. Res_Q eliminates validation debt and ensures peace of mind in an increasingly complex technology ecosystem. For more information, visit www.sware.com.
Media:
Colleen Burns
Colleen.Burns@sware.com
TABLE OF CONTENTS
Nathan McBride
Senior Vice President, IT
Xilio Therapeutics
Nathan McBride
Senior Vice President, IT
Xilio Therapeutics
Nathan McBride
Senior Vice President, IT
Xilio Therapeutics
Featured Resources
The future of life sciences validation and compliance is not so far away. Already, we are seeing life sciences companies rush to integrate AI where possible, while at the same time striving to manage risk with fewer human and material resources available.
Read the WhitepaperLearn how Nuvolo is leveraging a combination of Sware's Res_Q Platform and expert resources to deliver a fully GxP compliant offering to the life sciences industry, enabling Nuvolo and their customers to meet business goals.
Read the case studyManual computer software validation processes cost life sciences organizations up to 30% in additional project budget. As companies struggle to keep up with a surge of app and software integrations, they incur validation debt: the mounting cost of stretched resources, blanket testing, and missed GxP requirements.
Download the EbookValidation to Sware by
Res_Q was built to serve the unique, complex requirements around CSV for GxP systems. Leverage our intelligent validation automation platform and our deep compliance expertise to your benefit — reach out today to schedule a no-pressure session — We’re here to help you.